Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effect of Additional Chromosomal Abnormalities in Acute Promyelocytic Leukemia Treated With All-trans-Retinoic Acid: A Report of 17 Patients

Abstract

Seventeen cases of acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and combination chemotherapy at Tokyo Metropolitan Komagome Hospital between 1992 and 1999 were reviewed, and divided into 2 kary-otype-based cytogenetic groups. One group comprised 7 patients with either the typical t(15;17) alone or a normal karyotype, and the other group comprised 10 patients with additional karyotypic abnormalities. No patient had received prior chemotherapy or irradiation, and no cases were complicated by a history of myelodysplastic syndrome before the diagnosis of APL. There were no significant differences in clinical characteristics at disease presentation. Complete remission was achieved in all 17 patients and karyotypes of bone marrow cells normalized in all cases. No differences were found in relapse rate, overall survival, or disease-free survival between the 2 groups.

The analysis did not reveal any significant effect of additional chromosomal abnormalities on the prognosis of APL patients undergoing treatment with ATRA. However, a small number of patients were assessed in this study, and further cumulative studies are needed.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Berger R, Le Coniat M, Derre J, Vecchione D, Jonveaux P. Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities.Genes Chromosomes Cancer. 1991;3:332–337.

  2. 2.

    Schoch C, Haase D, Haferlach T, et al. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients.Br J Haematol. 1996;94:493–500.

  3. 3.

    Slack JL, Arthur DC, Lawrence D, et al. Secondary cytogenetic changes in acute promyelocytic leukemia—prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a cancer and leukemia group B study.J Clin Oncol. 1997;15:1786–1795.

  4. 4.

    Hiorns LR, Swansbury GJ, Mehta J, et al. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia.Br J Haematol. 1997;96:314–312.

  5. 5.

    Pandolfi PP, Alcalay M, Fagioli M, et al. Genomic variability and alternative splicing generate multiple PML/RARa transcripts that encode aberrant PML proteins and PML/RARa isoforms in acute promyelocytic leukaemia.EMBO J. 1992;11:1397–1407.

  6. 6.

    Huang W, Sun GL, Li XS, et al. Acute promyelocytic leukemia: clinical relevance of two major PML-RARa isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse.Blood. 1993;82:1264–1269.

  7. 7.

    Kanamaru A, Takemoto Y, Tanimoto M, et al.All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia.Blood. 1995;85:1202–1206.

  8. 8.

    Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy.Blood. 1997;90:1014–1021.

  9. 9.

    Avvisati G, Coco FL, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot study.Blood. 1996;88:1390–1398.

  10. 10.

    Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia.Blood. 1999;94:1192–1200.

  11. 11.

    Ogawa K, Shineha H, Abe R, et al. Acute promyelocytic leukemia with a history of RAEB in transformation and the 15/17 translocation.Jpn J Clin Hematol. 1989;30:67–71.

  12. 12.

    Dalton, Jr. WT, Cork A, Stass SA, Trujillo JM. Chronic myelomonocytic leukemia with trisomy 8 and related clone with trisomy 8 and t(15;17).Cancer Genet Cytogenet. 1988;32:287–292.

  13. 13.

    Detourmignies L, Castaigne S, Stoppa AM, et al. Therapy-related acute promyelocytic leukemia: a roport on 16 cases.J Clin Oncol. 1992;10:1430–1435.

  14. 14.

    Bhavnani M, Al Azzawi S, Liu Yin JA, Lucas GS. Therapy-related acute promyelocytic leukaemia.Br J Haematol. 1994;86:231–232.

Download references

Author information

Correspondence to Yasushi Okoshi or Hideki Akiyama or Natsu Kono or Tomoko Matsumura or Daisuke Mizuchi or Shin-Ichiro Mori or Kazuteru Ohashi or Hisashi Sakamaki.

About this article

Cite this article

Okoshi, Y., Akiyama, H., Kono, N. et al. Effect of Additional Chromosomal Abnormalities in Acute Promyelocytic Leukemia Treated With All-trans-Retinoic Acid: A Report of 17 Patients. Int J Hematol 73, 496–501 (2001). https://doi.org/10.1007/BF02994013

Download citation

Key words

  • Acute promyelocytic leukemia
  • All-trans-retinoic acid
  • Chromosomal abnormality